Zymeworks Inc
ZYME
View Detailed Chart
18.890USD
-0.195-1.02%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
1.33BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.02%
5 Days
+2.27%
1 Month
+11.51%
6 Months
+45.76%
Year to Date
+29.03%
1 Year
+42.24%
View Detailed Chart
TradingKey Stock Score of Zymeworks Inc
Currency: USD Updated: 2025-11-03Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zymeworks Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
24.611
Target Price
+28.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zymeworks Inc Highlights
StrengthsRisks
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Growing
The company is in a growing phase, with the latest annual income totaling USD 76.30M.
Undervalued
The company’s latest PE is -19.30, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 77.28M shares, increasing 1.58% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 71.98K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Zymeworks Inc Info
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Ticker SymbolZYME
CompanyZymeworks Inc
CEOMr. Kenneth H. (Ken) Galbraith
Websitehttps://www.zymeworks.com/
Related Instruments
+0.95%
-1.78%
-2.37%
-1.19%
+0.44%
+0.04%
+1.56%
-1.27%
-3.65%
-1.76%
+3.54%
-0.31%
-0.87%
+0.83%
-1.58%
-2.50%
-2.09%
-1.56%
0.00%
-0.67%Popular Symbols
